Literature DB >> 19643619

Optimal proportions of gelatin-resorcin-formalin components in aortic surgery.

Takashi Kunihara1, Kenji Iizuka, Shigeyuki Sasaki, Norihiko Shiiya, Fumihiro Sata, Yoshiro Matsui.   

Abstract

BACKGROUND: Gelatin-resorcin-formalin (GRF) glue, a haemostatic agent often employed for aortic surgery, has beneficial effects on early results in surgery for acute aortic dissection but may have late adverse effects, probably due to excess use of the activators such as formaldehyde and glutaraldehyde. The purpose of this study was to determine the optimal proportions of GRF components that minimise toxicity to human aortic smooth muscle cells and elastin with acceptable adhesive strength.
METHODS: (1) The degree of polymerisation was examined at various proportions (activator/gelatin+resorcinol=0%, 2%, 4%, 6%, 8% and 10%) to estimate adhesive strength. (2) (i) The toxicity of the activator was confirmed 24h after its supplementation to human aortic smooth muscle cells in various proportions (activator/human aortic smooth muscle cell=0%, 0.5%, 1%, 1.5%, 2% and 2.5%). (ii) The toxicity of GRF glue to human aortic smooth muscle cells was evaluated 1h and 60 h after its supplementation (activator/gelatin+resorcinol=0%, 2%, 4%, 6%, 8% and 10%). Another set of experiments in the same study was also performed. The only difference was that GRF glues were washed after polymerisation to exclude non-polymerised constituents. (3) Effects of 8%-GRF glue on toxicity to elastin derived from human aortic wall cells were investigated using an immunoblotting method.
RESULTS: (1) The polymerisation area increased dose dependently and that of the 10% activator/gelatin+resorcinol mixture was significantly wider than those of 6%, 4%, 2% and 0%, but had no significant difference from that of 8%. (2) (i) Human aortic smooth muscle cell death occurred in all dishes except activator-free dishes. (ii) Sixty hours after exposure to GRF glue, human aortic smooth muscle cell death occurred only in the 10% dish. In a washed GRF glue study, no human aortic smooth muscle cell death occurred in any dishes. (3) Toxicity to elastin was not significantly different between 8%-GRF glue and the control, whereas toxicity of elastase to elastin was significantly higher than for both the glue and the control.
CONCLUSIONS: An 8%-GRF glue provides lower toxicity to human aortic smooth muscle cells and elastin with an acceptable degree of polymerisation, and thus seems to be an optimal proportion for GRF glue.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19643619     DOI: 10.1016/j.ejcts.2009.06.032

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  6 in total

1.  A highly elastic and adhesive gelatin tissue sealant for gastrointestinal surgery and colon anastomosis.

Authors:  Tony Vuocolo; Roger Haddad; Glenn A Edwards; Russell E Lyons; Nancy E Liyou; Jerome A Werkmeister; John A M Ramshaw; Christopher M Elvin
Journal:  J Gastrointest Surg       Date:  2011-11-12       Impact factor: 3.452

Review 2.  The use of surgical glue in acute type A aortic dissection.

Authors:  Shinichi Suzuki; Munetaka Masuda; Kiyotaka Imoto
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-11-21

3.  Recent status of gelatin-resorcin-formalin glue for acute type A aortic dissection.

Authors:  Kiyotaka Imoto
Journal:  Gen Thorac Cardiovasc Surg       Date:  2011-05-06

4.  A case of ascending aortic pseudoaneurysm in a patient with aortic replacement.

Authors:  Yuichi Ishida; Yasuhito Sakano; Shin-ichi Ohki; Arata Muraoka; Kei Aizawa; Yoshio Misawa
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-04-28

5.  When and how to replace the aortic root in type A aortic dissection.

Authors:  Bradley G Leshnower; Edward P Chen
Journal:  Ann Cardiothorac Surg       Date:  2016-07

6.  Hemolytic anemia caused by aortic flap and inversion of felt strip after ascending aorta replacement.

Authors:  Masayuki Sakaguchi; Tamaki Takano
Journal:  J Cardiothorac Surg       Date:  2016-08-02       Impact factor: 1.637

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.